Cargando…

Time to abandon ampicillin plus gentamicin in favour of ampicillin plus ceftriaxone in Enterococcus faecalis infective endocarditis? A meta-analysis of comparative trials

BACKGROUND: Current guidelines recommend either ampicillin plus ceftriaxone (AC) or amoxicillin/ampicillin plus gentamicin (AG) with an equivalent class IB recommendation in Enterococcus faecalis endocarditis. However, previous observational studies suggest that AC might be favourable in terms of ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirna, Moritz, Topf, Albert, Schmutzler, Lukas, Hoppe, Uta C., Lichtenauer, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525249/
https://www.ncbi.nlm.nih.gov/pubmed/34751788
http://dx.doi.org/10.1007/s00392-021-01971-3
_version_ 1784800667569750016
author Mirna, Moritz
Topf, Albert
Schmutzler, Lukas
Hoppe, Uta C.
Lichtenauer, Michael
author_facet Mirna, Moritz
Topf, Albert
Schmutzler, Lukas
Hoppe, Uta C.
Lichtenauer, Michael
author_sort Mirna, Moritz
collection PubMed
description BACKGROUND: Current guidelines recommend either ampicillin plus ceftriaxone (AC) or amoxicillin/ampicillin plus gentamicin (AG) with an equivalent class IB recommendation in Enterococcus faecalis endocarditis. However, previous observational studies suggest that AC might be favourable in terms of adverse events. OBJECTIVES: To investigate whether AC is non-inferior to AG, and if it is associated with less adverse events. METHODS: In June 2021, a systematic literature search using the databases PubMed/MEDLINE, CDSR, CENTRAL, CCAs, EBM Reviews, Web of Science and LILACS was conducted by two independent reviewers. Studies were considered eligible if (P) patients included were ≥ 18 years of age and had IE with E. faecalis, (I) treatment with AC was compared to (C) treatment with AG and (O) outcomes on in-hospital mortality, nephrotoxicity and adverse events requiring drug withdrawal were reported. Odds ratios and 95% confidence intervals were calculated using random-effects models with the Mantel–Haenszel method, the Sidik–Jonkman estimator for τ(2) and the Hartung–Knapp adjustment. RESULTS: Treatment with AC was non-inferior to AG, as depicted by no significant differences in-hospital mortality, 3-month mortality, relapses or treatment failure. Furthermore, AC was associated with a lower prevalence of nephrotoxicity (OR 0.45 [0.26–0.77], p = 0.0182) and drug withdrawal due to adverse events (OR 0.11 [0.03–0.46], p = 0.0160) than AG. CONCLUSIONS: Treatment with AC was non-inferior to treatment with AG, and it was associated with a reduced prevalence of nephrotoxicity and drug withdrawal due to adverse events. Thus, combination therapy with AC appears favourable over AG in patients with E. faecalis IE. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-021-01971-3.
format Online
Article
Text
id pubmed-9525249
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-95252492022-10-02 Time to abandon ampicillin plus gentamicin in favour of ampicillin plus ceftriaxone in Enterococcus faecalis infective endocarditis? A meta-analysis of comparative trials Mirna, Moritz Topf, Albert Schmutzler, Lukas Hoppe, Uta C. Lichtenauer, Michael Clin Res Cardiol Original Paper BACKGROUND: Current guidelines recommend either ampicillin plus ceftriaxone (AC) or amoxicillin/ampicillin plus gentamicin (AG) with an equivalent class IB recommendation in Enterococcus faecalis endocarditis. However, previous observational studies suggest that AC might be favourable in terms of adverse events. OBJECTIVES: To investigate whether AC is non-inferior to AG, and if it is associated with less adverse events. METHODS: In June 2021, a systematic literature search using the databases PubMed/MEDLINE, CDSR, CENTRAL, CCAs, EBM Reviews, Web of Science and LILACS was conducted by two independent reviewers. Studies were considered eligible if (P) patients included were ≥ 18 years of age and had IE with E. faecalis, (I) treatment with AC was compared to (C) treatment with AG and (O) outcomes on in-hospital mortality, nephrotoxicity and adverse events requiring drug withdrawal were reported. Odds ratios and 95% confidence intervals were calculated using random-effects models with the Mantel–Haenszel method, the Sidik–Jonkman estimator for τ(2) and the Hartung–Knapp adjustment. RESULTS: Treatment with AC was non-inferior to AG, as depicted by no significant differences in-hospital mortality, 3-month mortality, relapses or treatment failure. Furthermore, AC was associated with a lower prevalence of nephrotoxicity (OR 0.45 [0.26–0.77], p = 0.0182) and drug withdrawal due to adverse events (OR 0.11 [0.03–0.46], p = 0.0160) than AG. CONCLUSIONS: Treatment with AC was non-inferior to treatment with AG, and it was associated with a reduced prevalence of nephrotoxicity and drug withdrawal due to adverse events. Thus, combination therapy with AC appears favourable over AG in patients with E. faecalis IE. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-021-01971-3. Springer Berlin Heidelberg 2021-11-09 2022 /pmc/articles/PMC9525249/ /pubmed/34751788 http://dx.doi.org/10.1007/s00392-021-01971-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Mirna, Moritz
Topf, Albert
Schmutzler, Lukas
Hoppe, Uta C.
Lichtenauer, Michael
Time to abandon ampicillin plus gentamicin in favour of ampicillin plus ceftriaxone in Enterococcus faecalis infective endocarditis? A meta-analysis of comparative trials
title Time to abandon ampicillin plus gentamicin in favour of ampicillin plus ceftriaxone in Enterococcus faecalis infective endocarditis? A meta-analysis of comparative trials
title_full Time to abandon ampicillin plus gentamicin in favour of ampicillin plus ceftriaxone in Enterococcus faecalis infective endocarditis? A meta-analysis of comparative trials
title_fullStr Time to abandon ampicillin plus gentamicin in favour of ampicillin plus ceftriaxone in Enterococcus faecalis infective endocarditis? A meta-analysis of comparative trials
title_full_unstemmed Time to abandon ampicillin plus gentamicin in favour of ampicillin plus ceftriaxone in Enterococcus faecalis infective endocarditis? A meta-analysis of comparative trials
title_short Time to abandon ampicillin plus gentamicin in favour of ampicillin plus ceftriaxone in Enterococcus faecalis infective endocarditis? A meta-analysis of comparative trials
title_sort time to abandon ampicillin plus gentamicin in favour of ampicillin plus ceftriaxone in enterococcus faecalis infective endocarditis? a meta-analysis of comparative trials
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525249/
https://www.ncbi.nlm.nih.gov/pubmed/34751788
http://dx.doi.org/10.1007/s00392-021-01971-3
work_keys_str_mv AT mirnamoritz timetoabandonampicillinplusgentamicininfavourofampicillinplusceftriaxoneinenterococcusfaecalisinfectiveendocarditisametaanalysisofcomparativetrials
AT topfalbert timetoabandonampicillinplusgentamicininfavourofampicillinplusceftriaxoneinenterococcusfaecalisinfectiveendocarditisametaanalysisofcomparativetrials
AT schmutzlerlukas timetoabandonampicillinplusgentamicininfavourofampicillinplusceftriaxoneinenterococcusfaecalisinfectiveendocarditisametaanalysisofcomparativetrials
AT hoppeutac timetoabandonampicillinplusgentamicininfavourofampicillinplusceftriaxoneinenterococcusfaecalisinfectiveendocarditisametaanalysisofcomparativetrials
AT lichtenauermichael timetoabandonampicillinplusgentamicininfavourofampicillinplusceftriaxoneinenterococcusfaecalisinfectiveendocarditisametaanalysisofcomparativetrials